Novel treatment of acute GVHD with donor bone marrow-derived M2 macrophages

2022 Fiscal Year Final Research Report

• Project/Area Number: 20K17376
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 54010:Hematology and medical oncology-related
• Research Institution: Mie University
• Principal Investigator: Hanaki Ryo 三重大学, 医学部附属病院, 助教 (40780408)
• Project Period (FY): 2020-04-01 – 2023-03-31
• Keywords: GVHD / 造血細胞移植 / M2 macrophage

Outline of Final Research Achievements

Graft-Versus Host disease (GVHD) is a serious complication of post-transplant immune effects in hematopoietic cell transplantation, the last resort in the treatment of refractory leukemia. In this study, we succeeded in reducing the severity of GVHD by inducing suppressive macrophages from cells derived from donor mice and injecting them into recipient mice that develop GVHD as if they were patients.

Free Research Field

造血細胞移植

Academic Significance and Societal Importance of the Research Achievements

GVHDに対する治療は主にステロイド、カルシニューリン阻害剤などの主にT細胞を標的とした免疫抑制剤が中心であり、長期に渡る内服継続によって生じる易感染性等の副作用や、それに加えてGVL効果の減弱などが問題となっており、新たな視点での新規治療の開発が待たれております。本研究結果は、GHVD発症機序に関する新たな知見となり、また、マクロファージを標的とした新しい視点での急性GVHD治療法の開発につながると考えます。